Malta - engelsk - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - epoprostenol sodium - powder and solvent for solution for infusion - epoprostenol sodium 0.5 mg - antithrombotic agents

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - epoprostenol sodium -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - epoprostenol sodium -

Irland - engelsk - HPRA (Health Products Regulatory Authority)

janssen-cilag international nv - epoprostenol - powder for solution for infusion - 1.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hipra malaysia sdn bhd - cloprostenol sodium -

Irland - engelsk - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - epoprostenol - powder and solvent for solution for infusion - 1.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol

Irland - engelsk - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - epoprostenol - powder and solvent for solution for infusion - 0.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoprostenol sodium 1.593mg equivalent to epoprostenol 1.5 mg - powder for injection - 1.5 mg - active: epoprostenol sodium 1.593mg equivalent to epoprostenol 1.5 mg excipient: arginine sodium hydroxide sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii and iv patients with: · idiopathic pulmonary arterial hypertension · familial pulmonary arterial hypertension · pulmonary arterial hypertension asscociated with the scleroderma spectrum of diseases.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoprostenol sodium 531ug equivalent to epoprostenol 500 mcg - powder for injection - 500 mcg - active: epoprostenol sodium 531ug equivalent to epoprostenol 500 mcg excipient: arginine sodium hydroxide sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii and iv patients with: · idiopathic pulmonary arterial hypertension · familial pulmonary arterial hypertension · pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

janssen-cilag international nv - epoprostenol - powder for solution for infusion - 0.5 milligram(s) - platelet aggregation inhibitors excl. heparin; epoprostenol